Effects of the Ganning formula on liver fibrosis in patients with chronic hepatitis B

Journal of Traditional Chinese Medicine

Volumn 31, Issue 4, 2011, Pages 282-287

  Deng, Xin ^a   Liang, Jian ^a   Wu, Fa Sheng ^a   Li, Yan Bo ^a   Tang, Yan Fang ^a  

^a RUIKANG HOSPITAL AFFILIATED TO GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Clinical observation; Ganning formula; Hepatitis B; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHINESE DRUG; COLLAGEN TYPE 4; ENTECAVIR; GAMMA GLUTAMYLTRANSFERASE; GANNING FORMULA; HYALURONIC ACID; LAMININ; PROCOLLAGEN; PROCOLLAGEN TYPE 3; UNCLASSIFIED DRUG; VIRUS DNA; HERBACEOUS AGENT;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B SCAN; BLOOD ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EVENING DOSAGE; FECES ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NONHUMAN; PATIENT MONITORING; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF RATING ANXIETY SCALE; SELF RATING DEPRESSION SCALE; SIDE EFFECT; SOCIAL ASPECT; SOCIAL DISABILITY SCREENING SCHEDULE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; VIRUS INHIBITION; WORLD HEALTH ORGANIZATION QUALITY OF LIFE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LIVER CIRRHOSIS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; DRUGS, CHINESE HERBAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860597885     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0254-6272(12)60005-3     Document Type: Article

References (32)

1. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterol 2004; 127: 1847-1849.
2. Sophie L, Boris J, Fatima T-C, Pascale G, Ariane M. Hepatic Fibrosis: Molecular Mechanisms and Drug Targets. Annu Rev Pharmacol Toxicol 2005; 45: 605-628.
3. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med 2009; 122: 3-4.
4. CT Wai, JK Greenson, RJ Fontana, JD Kalbfleisch, JA Marrero, HS Conjeevaram, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
5. Lu ZY, Zhong NS. Internal Medicine Science, 7th ed, (Chin). Beijing: People's Medical Publishing House; 2008: 446-447.
6. Chinese Society of Hepatology, Chinese Medical Association, and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for prevention and treatment of chronic hepatitis B. Chin J Infect Dis (Chin) 2005; 23: 421-431.
7. Liver Fibrosis Group, Chinese Society of Hepatology, Chinese Medical Association. Consensus on diagnosis and outcome assessment of liver fibrosis. Chin J Hepatol (Chin) 2002; 10: 327-328.
8. WHO. World Health Organisation WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment. Geneva; 1996.
9. Hao YT, Fang JQ. Introduction and Administration of the Chinese version of WHOQOL. Mod Rehabil (Chin) 2000; 4: 1123-1124.
10. Santini MT, Rainaldi G, Indovina PL. Multicelluar tumour spheroids in radiation biology. Int J Radiat Biol 1999; 75: 787-789.
11. Zhang MY. Manual of Rating Scales for Psychiatry (Chin). Changsha: Hunan Science and Technology Press; 1993: 162-164.
12. Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice. Chin J Hepatol (Chin) 2006; 14: 866-868.
13. Friedman SL, Bansal MB. Reversal of hepatic fibrosis-fact or fantasy? Hepatology 2006; 43: 82-88.
14. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19-25.
15. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, et al. A study on the seroepidemiology of hepatitis B in Chinese population aged over 3-years old. Chin J Epidemiol (Chin) 2005; 26: 655-658.
16. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988 May-Jun;8(3): 493-496.
17. Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB, et al. Study on the natural history of chronic hepatitis B. Zhonghua Ganzangbing Zazhi (Chin) 2002; 10: 46-48.
18. Deng X, Liang J, Zhou W, Qin LK Li LH. Clinical Observation on the Effect of Ganning Fang on Portal Hypertension of Hepatic Cirrhosis. J Tradit Chin Med (Chin) 2008; 49: 234-236.
19. Deng X, Liang J, Li YZ, Zhang XL. The protective effect of Ganning Fang on oxidative injury in cirrhosis rats. Chin J Integr Tradit West Med Dig (Chin) 2007; 15: 102-104.
20. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 791-799.
21. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterol 2006; 130: 2039-2049.
22. Chinese Society of Hepatology, Chinese Medical Association, and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for prevention and treatment of chronic hepatitis B (2010 edition). Chin Hepatol (Chin) 2011; 6: 1-15.
23. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, and Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459-1465.
24. Takahara T, Sollberg S, Muona P, Uitto J. Type VI collagen gene expression in experimental liver fibrosis: quantitation and partial distribution of mRNAs, and immunodetection of the protein. Liver 1995; 15: 78-86.
25. Liu J, Wang J, Lu Y. Serum fibrosis markers in diagnosing liver fibrosis. Chin J Intern Med (Chin) 2006; 45: 475-477.
26. Li Q, Ou XJ, Li J, Jia JD, Wang BE. The contrast study of serum liver fibrosis indexes and liver pathology. Chin J Clin Hepatol (Chin) 2004; 20: 155-157.
27. Dong HY, Li Y, Zhao GM. The control study of serum liver fibrosis indexes and liver pathology. Int J Epidemiol Infect Dis (Chin) 2006; 33: 81-82.
28. Yuan Z. Clinical applicative characteristics of biopsychosocial medical mode. Chin J Clin Rehabil 2005; 9: 252-253.
29. Deng X, Liang J, Wu FS, Li YB, Tang YF. Effects of traditional Chinese medicine on quality of life in patients with liver cirrhosis secondary to hepatitis. LiShizhen Med Mater Med Res (Chin) 2010; 21: 3314-3316.
30. Kim SH, Oh EG, Lee WH. Symptom experience, psychological distress, and quality of life in Korean patients with liver cirrhosis: a cross-sectional survey. Int J Nurs Stud 2006; 43: 1047-1056.
31. Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-476.
32. Jin S, Yan L, Li B, Wen T, Zhao J, Zeng Y et al. Quality of life and psychologic distress of recipients after adult living-donor liver transplantation (LDLT)-A study from mainland China. Transplant Proc 2010; 42: 2611-2616.